Elanco Animal Health shares surge 10.22% premarket after reporting stronger-than-expected Q3 revenue growth and raising full-year guidance.

Elanco Animal Health surged 10.22% in premarket trading following the release of its Q3 2025 earnings report, which exceeded expectations. The company reported revenue of $1,137 million, a 10% year-over-year increase, driven by strong performance in both Pet Health and Farm Animal segments. Key highlights included a 9% organic constant currency growth, adjusted net income of $94 million, and a raised full-year revenue guidance to $4,645–$4,670 million. Strategic product launches like Credelio Quattro and Zenrelia, along with improved net leverage ratio targets, reinforced optimism. The adjusted EPS of $0.19 outperformed the IBES estimate of $0.13, and the company announced disciplined debt management and innovation-driven growth. These results, coupled with a revised 2025 outlook, directly fueled the premarket rally.